Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EPS (Basic) (2018 - 2025)

Addex Therapeutics' EPS (Basic) history spans 8 years, with the latest figure at -$0.03 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 57.29% to -$0.03 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.77, a 111.95% decrease, with the full-year FY2025 number at -$0.07, down 190.57% from a year prior.
  • EPS (Basic) came in at -$0.03 for Q4 2025, down from $0.06 in the prior quarter.
  • The five-year high for EPS (Basic) was $7.78 in Q2 2024, with the low at -$1.77 in Q1 2023.
  • Historically, EPS (Basic) has averaged -$0.0 across 5 years, with a median of -$0.08 in 2024.
  • Biggest five-year swings in EPS (Basic): tumbled 21158.3% in 2023 and later skyrocketed 592.65% in 2024.
  • Year by year, EPS (Basic) stood at -$0.56 in 2021, then skyrocketed by 103.3% to $0.02 in 2022, then crashed by 494.86% to -$0.07 in 2023, then decreased by 2.8% to -$0.08 in 2024, then skyrocketed by 57.29% to -$0.03 in 2025.
  • Business Quant data shows EPS (Basic) for ADXN at -$0.03 in Q4 2025, $0.06 in Q2 2025, and -$0.8 in Q1 2025.